Allurion Technologies Inc... (ALUR)
NYSE: ALUR
· Real-Time Price · USD
2.30
-0.07 (-2.95%)
At close: May 01, 2025, 3:59 PM
2.31
0.40%
After-hours: May 01, 2025, 06:00 PM EDT
Company Description
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight.
Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.
The company is headquartered in Natick, Massachusetts.
Allurion Technologies Inc.
| Country | United States |
| IPO Date | Mar 29, 2021 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 134 |
| CEO | Dr. Shantanu K. Gaur M.D. |
Contact Details
Address: 11 Huron Drive Natick, Massachusetts United States | |
| Website | https://www.allurion.com |
Stock Details
| Ticker Symbol | ALUR |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001964979 |
| CUSIP Number | 02008G102 |
| ISIN Number | US02008G1022 |
| Employer ID | 00-0000000 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shantanu K. Gaur M.D. | Co-Founder, Chief Executive Officer, President, Principal Financial & Accounting Officer and Director |
| Brendan Michael Gibbons J.D. | Chief Legal Officer & Corporate Secretary |
| Ojas A. Buch | Chief Operating Officer |
| Dr. Ram Chuttani M.D. | MD, Chief Medical Officer & Founding Partner |
| Dr. Samuel G. Levy | Co-Founder |
| Matt Wright | Vice President of People |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2025 | S-3 | Filing |
| Apr 18, 2025 | 424B3 | Filing |
| Apr 18, 2025 | 424B3 | Filing |
| Apr 17, 2025 | 4 | Filing |
| Apr 17, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Apr 17, 2025 | 8-K | Current Report |
| Apr 10, 2025 | 8-K | Current Report |
| Apr 03, 2025 | DEFA14A | Filing |
| Apr 03, 2025 | 8-K | Current Report |
| Apr 01, 2025 | 4 | Filing |